Table of Contents Author Guidelines Submit a Manuscript
International Journal of Hepatology
Volume 2013, Article ID 572307, 7 pages
http://dx.doi.org/10.1155/2013/572307
Review Article

Gd-EOB-DTPA-Enhanced MRI for Detection of Liver Metastases from Colorectal Cancer: A Surgeon’s Perspective!

University of California, Irvine, 333 The City Boulevard West, Suite 1205, Orange, CA 92868, USA

Received 29 December 2012; Revised 8 March 2013; Accepted 22 March 2013

Academic Editor: Jorge Ortiz

Copyright © 2013 Kelly J. Lafaro et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. D. Smith and J. L. McCall, “Systematic review of tumour number and outcome after radical treatment of colorectal liver metastases,” British Journal of Surgery, vol. 96, no. 10, pp. 1101–1113, 2009. View at Publisher · View at Google Scholar · View at Scopus
  2. L. H. Xu, S. J. Cai, G. X. Cai, and W. J. Peng, “Imaging diagnosis of colorectal liver metastases,” World Journal of Gastroenterology, vol. 17, no. 42, pp. 4654–4659, 2011. View at Google Scholar
  3. K. T. Nguyen, A. Laurent, I. Dagher et al., “Minimally invasive liver resection for metastatic colorectal cancer: a multi-institutional, international report of safety, feasibility, and early outcomes,” Annals of Surgery, vol. 250, no. 5, pp. 842–848, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. J. Ward, “New MR techniques for the detection of liver metastases,” Cancer Imaging, vol. 6, pp. 33–42, 2006. View at Google Scholar · View at Scopus
  5. R. Malafosse, C. Penna, A. Sa Cunha, and B. Nordlinger, “Surgical management of hepatic metastases from colorectal malignancies,” Annals of Oncology, vol. 12, no. 7, pp. 887–894, 2001. View at Publisher · View at Google Scholar · View at Scopus
  6. C. Charnsangavej, B. Clary, Y. Fong, A. Grothey, T. M. Pawlik, and M. A. Choti, “Selection of patients for resection of hepatic colorectal metastases: expert consensus statement,” Annals of Surgical Oncology, vol. 13, no. 10, pp. 1261–1268, 2006. View at Publisher · View at Google Scholar · View at Scopus
  7. J. N. Vauthey, T. M. Pawlik, E. K. Abdalla et al., “Is Extended Hepatectomy for Hepatobiliary Malignancy Justified?” Annals of Surgery, vol. 239, no. 5, pp. 722–732, 2004. View at Publisher · View at Google Scholar · View at Scopus
  8. E. K. Abdalla, C. C. Barnett, D. Doherty, S. A. Curley, and J. N. Vauthey, “Extended hepatectomy in patients with hepatobiliary malignancies with and without preoperative portal vein embolization,” Archives of Surgery, vol. 137, no. 6, pp. 675–681, 2002. View at Google Scholar · View at Scopus
  9. C. J. Zech, K. A. Herrmann, M. F. Reiser, and S. O. Schoenberg, “MR imaging in patients with suspected liver metastases: value of liver-specific contrast agent Gd-EOB-DTPA,” Magnetic Resonance in Medical Sciences, vol. 6, no. 1, pp. 43–52, 2007. View at Publisher · View at Google Scholar · View at Scopus
  10. M. C. Niekel, S. Bipat, and J. Stoker, “Diagnostic imaging of colorectal liver metastases with CT, MR imaging, FDG PET, and/or FDG PET/CT: a meta-analysis of prospective studies including patients who have not previously undergone treatment,” Radiology, vol. 257, no. 3, pp. 674–684, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. M. S. Pedro, R. C. Semelka, and L. Braga, “MR imaging of hepatic metastases,” Magnetic Resonance Imaging Clinics of North America, vol. 10, no. 1, pp. 15–29, 2002. View at Publisher · View at Google Scholar · View at Scopus
  12. I. M. Danet, R. C. Semelka, P. Leonardou et al., “Spectrum of MRI appearances of untreated metastases of the liver,” American Journal of Roentgenology, vol. 181, no. 3, pp. 809–817, 2003. View at Google Scholar · View at Scopus
  13. A. Benko, M. Fraser-Hill, P. Magner et al., “Canadian Association of Radiologists: consensus guidelines for the prevention of contrast-induced nephropathy,” Canadian Association of Radiologists Journal, vol. 58, no. 2, pp. 79–87, 2007. View at Google Scholar · View at Scopus
  14. R. C. Semelka, D. R. Martin, C. Balci, and T. Lance, “Focal liver lesions: comparison of dual-phase CT and multisequence multiplanar MR imaging including dynamic gadolinium enhancement,” Journal of Magnetic Resonance Imaging, vol. 13, no. 3, pp. 397–401, 2001. View at Publisher · View at Google Scholar · View at Scopus
  15. T. Ichikawa, K. Saito, N. Yoshioka et al., “Detection and characterization of focal liver lesions: a Japanese phase III, multicenter comparison between gadoxetic acid disodium-enhanced magnetic resonance imaging and contrast-enhanced computed tomography predominantly in patients with hepatocellular carcinoma and chronic liver disease,” Investigative Radiology, vol. 45, no. 3, pp. 133–141, 2010. View at Publisher · View at Google Scholar · View at Scopus
  16. A. Frydrychowicz, M. Lubner, J. Brown et al., “Hepatobiliary MR Imaging with Gadolinium based contrast agents,” Journal of Magnetic Resonance Imaging, vol. 35, pp. 492–511, 2012. View at Google Scholar
  17. J. W. Finley, “Manganese absorption and retention by young women is associated with serum ferritin concentration,” American Journal of Clinical Nutrition, vol. 70, no. 1, pp. 37–43, 1999. View at Google Scholar · View at Scopus
  18. C. de Haën, V. Lorusso, and P. Tirone, “Hepatic transport of gadobenate dimeglumine in TR-rats,” Academic Radiology, vol. 3, supplement 2, pp. S452–S454, 1996. View at Google Scholar
  19. A. Spinazzi, V. Lorusso, G. Pirovano, and M. Kirchin, “Safety, tolerance, biodistribution, and MR imaging enhancement of the liver with gadobenate dimeglumine: results of clinical pharmacologic and pilot imaging studies in nonpatient and patient volunteers,” Academic Radiology, vol. 6, no. 5, pp. 282–291, 1999. View at Google Scholar · View at Scopus
  20. B. Van Beers, C. Pastor, and H. Hussain, “Primovist, eovist: what to expect?” Journal of Hepatology, vol. 57, pp. 421–429, 2012. View at Google Scholar
  21. P. Reimer, E. J. Rummeny, K. Shamsi et al., “Phase II clinical evaluation of Gd-EOB-DTPA: dose, safety aspects, and pulse sequence,” Radiology, vol. 199, no. 1, pp. 177–183, 1996. View at Google Scholar · View at Scopus
  22. P. Reimier, E. J. Rummeny, H. E. Daldrup et al., “Enhancement characteristics of liver metastases, hepatocellular carcinomas, and hemangiomas with Gd-EOB-DTPA: preliminary results with dynamic MR imaging,” European Radiology, vol. 7, no. 2, pp. 275–280, 1997. View at Google Scholar · View at Scopus
  23. P. Reimer, G. Schneider, and W. Schima, “Hepatobiliary contrast agents for contrast-enhanced MRI of the liver: properties, clinical development and applications,” European Radiology, vol. 14, no. 4, pp. 559–578, 2004. View at Publisher · View at Google Scholar · View at Scopus
  24. H. J. Weinmann, G. Schuhmann-Giampieri, H. Schmitt-Willich, H. Vogler, T. Frenzel, and H. Gries, “A new lipophilic gadolinium chelate as a tissue-specific contrast medium for MRI,” Magnetic Resonance in Medicine, vol. 22, no. 2, pp. 233–237, 1991. View at Google Scholar · View at Scopus
  25. A. Kitao, Y. Zen, O. Matsui et al., “Hepatocellular carcinoma: signal intensity at gadoxetic acid-enhanced MR imaging-correlation with molecular transporters and histopathologic features,” Radiology, vol. 256, pp. 817–826, 2010. View at Google Scholar
  26. B. Hamm, T. Staks, A. Mühler et al., “Phase I clinical evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: safety, pharmacokinetics, and MR imaging,” Radiology, vol. 195, no. 3, pp. 785–792, 1995. View at Google Scholar · View at Scopus
  27. N. Dahlström, A. Persson, N. Albiin, O. Smedby, and T. B. Brismar, “Contrast-enhanced magnetic resonance cholangiography with Gd-BOPTA and Gd-EOB-DTPA in healthy subjects,” Acta Radiologica, vol. 48, no. 4, pp. 362–368, 2007. View at Publisher · View at Google Scholar · View at Scopus
  28. H. S. Thomsen, “Nephrogenic systemic fibrosis: history and epidemiology,” Radiologic Clinics of North America, vol. 47, no. 5, pp. 827–831, 2009. View at Publisher · View at Google Scholar · View at Scopus
  29. R. Hammerstingl, A. Huppertz, J. Breuer et al., “Diagnostic efficacy of gadoxetic acid (Primovist)-enhanced MRI and spiral CT for a therapeutic strategy: comparison with intraoperative and histopathologic findings in focal liver lesions,” European Radiology, vol. 18, no. 3, pp. 457–467, 2008. View at Publisher · View at Google Scholar · View at Scopus
  30. R. K. G. Do, H. Rusinek, and B. Taouli, “Dynamic contrast-enhanced MR imaging of the liver: current status and future directions,” Magnetic Resonance Imaging Clinics of North America, vol. 17, no. 2, pp. 339–349, 2009. View at Publisher · View at Google Scholar · View at Scopus
  31. R. N. Low, “Abdominal MRI advances in the detection of liver tumours and characterisation,” The Lancet Oncology, vol. 8, pp. 525–535, 2007. View at Google Scholar
  32. M. Bollow, M. Taupitz, B. Hamm, T. Staks, K. J. Wolf, and H. J. Weinmann, “Gadolinium-ethoxybenzyl-DTPA as a hepatobiliary contrast agent for use in MR cholangiography: results of an in vivo phase-I clinical evaluation,” European Radiology, vol. 7, no. 1, pp. 126–132, 1997. View at Google Scholar · View at Scopus
  33. J. Petersein, A. Spinazzi, A. Giovagnoni et al., “Focal liver lesions: evaluation of the efficacy of gadobenate dimeglumine in MR imaging—a multicenter phase III clinical study,” Radiology, vol. 215, no. 3, pp. 727–736, 2000. View at Google Scholar · View at Scopus
  34. Y. K. Kim, J. M. Lee, and C. S. Kim, “Gadobenate dimeglumine-enhanced liver MR imaging: value of dynamic and delayed imaging for the characterization and detection of focal liver lesions,” European Radiology, vol. 14, no. 1, pp. 5–13, 2004. View at Publisher · View at Google Scholar · View at Scopus
  35. T. J. Vogl, S. Kümmel, R. Hammerstingl et al., “Liver tumors: comparison of MR imaging with Gd-EOB-DTPA and Gd-DTPA,” Radiology, vol. 200, no. 1, pp. 59–67, 1996. View at Google Scholar · View at Scopus
  36. A. Huppertz, T. Balzer, A. Blakeborough et al., “Improved detection of focal liver lesions at MR imaging: multicenter comparison of gadoxetic acid-enhanced MR images with intraoperative findings,” Radiology, vol. 230, no. 1, pp. 266–275, 2004. View at Publisher · View at Google Scholar · View at Scopus
  37. D. A. Bluemke, D. Sahani, M. Amendola et al., “Efficacy and safety of MR imaging with liver-specific contrast agent: U.S. multicenter phase III study,” Radiology, vol. 237, no. 1, pp. 89–98, 2005. View at Publisher · View at Google Scholar · View at Scopus
  38. J. Halavaara, J. Breuer, C. Ayuso et al., “Liver tumor characterization: comparison between liver-specific gadoxetic acid disodium-enhanced MRI and biphasic CT—a multicenter trial,” Journal of Computer Assisted Tomography, vol. 30, no. 3, pp. 345–354, 2006. View at Publisher · View at Google Scholar · View at Scopus
  39. K. Shimada, H. Isoda, Y. Hirokawa, S. Arizono, T. Shibata, and K. Togashi, “Comparison of gadolinium-EOB-DTPA-enhanced and diffusion-weighted liver MRI for detection of small hepatic metastases,” European Radiology, vol. 20, no. 11, pp. 2690–2698, 2010. View at Publisher · View at Google Scholar · View at Scopus
  40. O. F. Donati, T. F. Hany, C. S. Reiner et al., “Value of retrospective fusion of PET and MR images in detection of hepatic metastases: comparison with 18F-FDG PET/CT and Gd-EOB-DTPA-enhanced MRI,” Journal of Nuclear Medicine, vol. 51, no. 5, pp. 692–699, 2010. View at Google Scholar · View at Scopus
  41. H. J. Seo, M. J. Kim, J. D. Lee, W. S. Chung, and Y. E. Kim, “Gadoxetate disodium-enhanced magnetic resonance imaging versus contrast-enhanced 18F-fluorodeoxyglucose positron emission tomography/computed tomography for the detection of colorectal liver metastases,” Investigative Radiology, vol. 46, no. 9, pp. 548–555, 2011. View at Google Scholar
  42. D. Löwenthal, M. Zeile, W. Y. Lim et al., “Detection and characterisation of focal liver lesions in colorectal carcinoma patients: comparison of diffusion-weighted and Gd-EOB-DTPA enhanced MR imaging,” European Radiology, vol. 21, no. 4, pp. 832–840, 2011. View at Publisher · View at Google Scholar · View at Scopus
  43. W. S. Chung, M. J. Kim, Y. E. Chung et al., “Comparison of gadoxetic acid-enhanced dynamic imaging and diffusion-weighted imaging for the preoperative evaluation of colorectal liver metastases,” Journal of Magnetic Resonance Imaging, vol. 34, no. 2, pp. 345–353, 2011. View at Publisher · View at Google Scholar · View at Scopus
  44. A. Muhi, T. Ichikawa, U. Motosugi et al., “Diagnosis of colorectal hepatic metastases: comparison of contrast-enhanced CT, contrast-enhanced US, superparamagnetic iron oxide-enhanced MRI, and gadoxetic acid-enhanced MRI,” Journal of Magnetic Resonance Imaging, vol. 34, no. 2, pp. 326–335, 2011. View at Publisher · View at Google Scholar · View at Scopus
  45. L. Chen, J. Zhang, L. Zhang et al., “Meta-analysis of gadoxetic acid disodium (Gd-EOB-DTPA)-enhanced magnetic resonance imaging for the detection of liver metastases,” PLoS One, vol. 7, no. 11, 2012. View at Publisher · View at Google Scholar
  46. V. Berger-Kulemann, W. Schima, S. Baroud et al., “Gadoxetic acid-enhanced 3.0T MR imaging versus multidetector-row CT in the detection of colorectal metastases in fatty liver using intraoperative ultrasound and histopatholgy as a standard of reference,” European Journal of Surgical Oncology, vol. 38, no. 8, pp. 670–676, 2012. View at Google Scholar
  47. C. J. Zech, L. Grazioli, E. Jonas et al., “Health-economic evaluation of three imaging strategies in patients with suspected colorectal liver metastases: Gd-EOB-DTPA-enhanced MRI vs. extracellular contrast media-enhanced MRI and 3-phase MDCT in Germany, Italy and Sweden,” European Radiology, vol. 19, supplement 3, pp. S753–S763, 2009. View at Publisher · View at Google Scholar · View at Scopus